echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > The FDA Advisory Committee voted in favour of APKS 3831 for the treatment of schizophrenia and biplex disorder.

    The FDA Advisory Committee voted in favour of APKS 3831 for the treatment of schizophrenia and biplex disorder.

    • Last Update: 2020-10-17
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Bipolar disorder (formerly known as manic depression) is characterized by depression alternating with mania, or mild mania.
    mania is mainly manifested in excessive activity and non-conformity with the outside world of high mood.
    usually in their teens, twenties or thirties.
    pharmaceutical company Alkermes announced today that the U.S. Food and Drug Administration's (FDA) Advisory Committee on Psychopharmaceuticals and the Advisory Committee on Drug Safety and Risk Management voted in favour of APKS 3831 (Otoxepine/Shamedofen) for the treatment of schizophrenia and biphasia.
    APKS 3831 is a new oral atypical antipsychotic candidate.
    FDA Committee found that shamedofen in ALKS 3831 was effective in reducing the weight gain associated with oxycoddm, and that the safety of ALKS 3831 had been fully demonstrated.
    . Craig Hopkinson, Chief Medical Officer and Executive Vice President of Research and Development at
    Alkermes, said, "Today's outcome is a milestone for patients with schizophrenia and biplex disorder, clinicians, and patient families.
    We look forward to working with the FDA to complete a follow-up review of the drug."
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.